MAPT and Alzheimer disease: The overarching goal of this present study was to validate the diagnostic accuracy of NULISA-quantified plasma p-tau biomarkers for the detection of Alzheimer’s disease Aβ and tau pathology via head-to-head comparisons with Simoa immunoassay-based methods.